



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 37/02, C07K 7/10	A1	(11) International Publication Number: WO 93/25222 (43) International Publication Date: 23 December 1993 (23.12.93)
(21) International Application Number: PCT/US93/05659 (22) International Filing Date: 11 June 1993 (11.06.93) (30) Priority data: 07/896,958 11 June 1992 (11.06.92) US (71) Applicant: SMITHKLINE BEECHAM CORPORATION [US/US]; Corporate Patents-U.S., UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (72) Inventors: CLARK, Michael, Thomas ; 1405 Wyndham Drive, Downingtown, PA 19335 (US). GYURIK, Robert, J. ; 1401 Dowlin Forge Road, Downingtown, PA 19335 (US). LEWIS, Sharon, K. ; 115 North Laurel Lane, Ex-ton, PA 19341 (US). MURRAY, Marianne, C. ; 405 Virginia Drive, Coatesville, PA 19320 (US). RAYMOND, Matthew, J. ; 250-2B Iven Avenue, St. Davids, PA 19087 (US).		(74) Agents: JERVIS, Herbert, H. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S., UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US). (81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: STABILIZED SOMATOTROPIN FOR PARENTERAL ADMINISTRATION (57) Abstract A stabilized complex comprising a growth hormone and an aromatic aldehyde. Specifically, the complex comprises porcine somatotropin and a substituted benzaldehyde and to a method of providing a prolonged release of the somatotropin and improved feed efficiency in animals.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

STABILIZED SOMATOTROPIN FOR PARENTERAL
ADMINISTRATION

5

Field of the Invention

This invention relates to a complex comprising a growth hormone (also referred to as a somatotropin) and an aromatic aldehyde. More specifically, this invention relates to a porcine somatotropin (PST)-aromatic aldehyde complex and to a method of producing stable PST compositions resulting in improved feed efficiency in the swine and a prolonged release of the PST.

10

Background of the Invention

When porcine somatotropin (PST) is administered to pigs on a daily basis a marked improvement in feed efficiency, i.e., feed-to-gain, the animal takes in less food than control animals while gaining weight at the same or greater level. However, it is inconvenient to administer drugs to the swine on a daily basis because of the large expense and amount of time required to deliver the drug to each member of a large group of animals. It would, therefore, be more feasible to apply a single dose and have the PST release over a prolonged period of time. It would appear the easiest way to administer PST would be in a feed, however, like most proteins and macromolecular drugs, PST is not orally bioavailable. In general, the literature has not shown significant ability to deliver proteins and peptides via the oral route. The use of salicylates and mineral oil to enhance oral delivery of these drugs is disclosed in E.P. Application No. 0177342. U.S. Patent 4,548,922, further discloses the use of steroid enhancers, such as fusidic acid.

15

20

25

Parenteral administration, for example, implants have been employed with other macromolecular drugs to give a prolonged release as disclosed in U.S. Patent No. 4,666,704. PST is an unstable protein susceptible to enzymatic, as well as aqueous degradation. It reacts with itself and is readily cleaved by proteases. Indeed, the instability of the PST implant is thought to be due to the proteases that are generated at the implantation site because of the inflammatory response that takes place (U.S. Patent 5,015,627). It is because of this instability that the administration of PST to swine has hitherto been only marginally, if at all successful. (See for example: U.S. Patents 4,837,381; 4,857,505; 5,045,312, and EP Applications 0193917 and 0458064).

30

35

There is a commercial need for improved prolonged release implants for parenteral administration of macromolecular drugs having growth hormone activity.

- 2 -

It is, therefore, an object of this invention to provide a composition and method for stabilizing and releasing a biological active growth hormone in animals over a prolonged period of time.

It is a further object of this invention to provide a stable form of PST which will release in swine over a prolonged period of time and which results in improved bioavailability and feed efficiency.

Description of Invention


In accordance with this invention, it has been discovered that when PST is reacted with an aromatic aldehyde a complex is formed which results in improved feed efficiency, i.e., weight gain and feed-to-gain ratio for the animals. The new complex not only has the same bioactivity as PST, but also provides efficacy over a sustained period similar to daily injections of PST.

As mentioned above, several attempts were made to prepare a PST product which would overcome the above noted disadvantages and could be successfully administered to swine. For example, U.S. Patent 5,015,627 discloses PST and leupeptin a tripeptide aldehyde mixed as dry powders, granulated and implants formed from the granulation. These implants were not efficacious.

Unexpectedly, it was discovered that when PST and an aromatic aldehyde of this invention were dissolved in water and the complex was isolated from the solution, a crystalline product resulted which provided a prolonged release of the somatotropin. The complex may be isolated from the aqueous solution by any method well known to the art, such as, for example, concentration, evaporation or lyophilization. Implants prepared from the complex and administered to pigs resulted in a sustained plasma PST level of up to seven days.

The aromatic aldehydes which are present in the complex and employed in the methods of this invention are preferably represented by the following formula

Formula 1



wherein X is CHO or CH₂CHO and each of R₁ and R₂ can be hydrogen, hydroxy, methoxy, ethoxy, methyl or ethyl.

- 3 -

Preferred aromatic aldehydes present in the complex and method of this invention are compounds of Formula 1 in which X is CHO and each of R₁ and R₂ is hydroxy or methoxy. A particularly preferred aromatic aldehyde present in the complex and method of this invention is 2 hydroxy-3-methoxy benzaldehyde. This aldehyde is also known as o-vanillin.

The aromatic aldehydes which are employed to prepare the stable PST complex of this invention and their method of preparation is well known to the art.

In a preferred embodiment the complex of the invention also comprises an animal growth hormone, such as, for example, human, bovine, avian, porcine, equine or ovine. Advantageously the complex and methods are applicable to porcine somatotropin.

Most advantageously the complex of this invention comprises 2-hydroxy-3-methoxy benzaldehyde and porcine somatotropin.

The aromatic aldehyde of Formula 1 may be present in the complex from about 0.5% to about 10% by weight. Preferably, the aromatic aldehyde may be present from about 0.5% to about 5.0% by weight.

The aromatic aldehyde of Formula 1 and PST complexes of this invention were prepared as follows:

Example 1

20	Porcine Somatotropin	99% w/w
	Aromatic Aldehyde of Formula 1	1.0% w/w

The PST and the aldehyde were dissolved in water, and reacted at 39°C for 6 to 24 hours. The water is slowly driven off and the resulting product is suspended in ethanol. The suspension is filtered and the precipitate dried overnight in a vacuum oven resulting in dried crystals.

The crystalline complex are formed into 35 mg pellets (implants) with a 3/16 inch punch and die and pressed to above 500 PSI.

Example 2

	Porcine Somatotropin	99.0% w/w
30	2-Hydroxy-3-Methoxy benzaldehyde	1.0% w/w

The complex and implants were prepared following the procedure of Example 1.

Example 3

	Porcine Somatotropin	99.0% w/w
35	4-Hydroxy-3-Methoxy benzaldehyde	1.0% w/w

Example 4

	Porcine Somatotropin	99.0% w/w
	4-Methoxy benzaldehyde	1.0% w/w

- 4 -

The above complexes were prepared following the procedure of Example 1.

The shape of the pellets or implants is not critical and any configuration suitable for implantation may be employed. In addition to the somatotropin and the aromatic aldehyde, it may be advantageous to include other pharmaceutical
5 excipients in the compositions of this invention. For example, the implant may contain lubricants, such as, magnesium stearate or stearic acid, fillers, such as, sucrose or lactose and binders, such as, acacia, polyvinylpyrrolidone or gelatin.

The compositions of this invention may be administered to an animal parenterally employing any of the known implantation methods, such as
10 subcutaneous, intramuscular and intraperitoneal. Preferably, the implant composition is subcutaneously implanted in an animal employing any well known technique.

Animals which are treated in this manner may include, without limitations, mammals such as cattle, sheep, goats, swine and the like, and birds such as poultry.

15 The following procedure was employed to determine plasma PST levels, feed consumption, average daily gain and feed-to-gain.

Pigs were housed in a barn and acclimated 3-4 weeks to pens containing 7-8 pigs per pen. Within each pen, pigs had access to a heated shelter and an ad libitum feed and water.

20 When most of the pigs reached approximately 75 kg, their weights were statistically compared and allotted to 4 different treatments, 9 pigs per treatment. The starting day was considered day 0, on which body weights, control blood samples, and implants were initiated. At the end of 21 days, the pigs were removed from the study.

25 The pigs were injected with 1 pellet (depending on treatment) S.C. behind the ear a commercial livestock implant gun was used and the site of administration was swabbed with 70% ETOH. Pigs treated daily at 5mg/head/day were injected with a 1 1/2 inch 16g needle in the neck area. Treatment was as follows:

- 30
1. Control - sham implant
 2. PST - daily injection - (5 mg/head/day)
 3. PST - o-vanillin implant - 1 pellet (35 mg PST)
 4. PST - leupeptin implant - 1 pellet (35 mg PST)

35 Blood samples were drawn from the snared pig via jugular vein, using a vacutainer with a 1 1/2 inch needle. The blood was allowed to clot, centrifuged, and plasma removed. The plasma samples were frozen for PST determinations which were assayed at a later date.

- 5 -

Feed Consumption

All pigs received Enhanced Finisher diet #634 throughout the study. On day zero, two bags of feed were added to feeder and an initial weight taken. The feeders were checked daily and a bag of preweighed food was added as needed (feeders were never allowed to empty). A final weight of feeder was taken on the day all pigs were removed from a pen. The final weight was subtracted from initial weight and this was added to total feed added which equals Total Feed Consumption per pen.

		Initial weight of feeder
10	-	<u>Final weight of feeder</u>
		Total
	+	<u>Total weight of bags of feed added</u>
		Total feed consumption per pen.

The pigs were weighed in kilograms individually on day zero and at seven day intervals throughout the study. Overall Average Daily Gain was derived by subtracting the initial weight on day zero from the pigs final weight and dividing by the number of days on study.

Feed-to-Gain per pen during the study was derived by adding all feed consumed per pen and dividing by total weight gain per pen.

The Average Daily Gain (ADG) and Feed-to-Gain results are presented in the following Table:

Table 1

PST Treatment	Average Daily Gain, Kg	% Increase over Control	Feed to Gain Ratio	% of Control
Control (no PST)	0.71	---	4.4	---
5 mg/head/day	0.86	21	2.7	39
o-vanillin/PST (1 pellet)	0.79	11.9	3.52	21
30 (35 mg)				
leupeptin/pST (1 pellet)	0.70	-1.4	4.12	6
(35 mg)				

The results of the plasma PST levels indicate that the daily injection of PST demonstrates very little, if any, plasma PST levels after 24 hours. In contrast, after implantation of the pellets of this invention, a sustained plasma PST level was noted.

- 6 -

The above results clearly indicate when the o-vanillin/PST complex is administered to pigs by implantation, there is an increase over the control in both the average daily gain and feed-to-gain observed in the pigs.


5 Furthermore, the results indicate that it is not necessary to add a protease inhibitor with the PST. We show now that a non-protease inhibitor (o-vanillin) interacts in a positive manner with PST to maintain efficacy over a 21 day period.

10 The method in accordance with this invention comprises parenterally administering to an animal organism the above PST - aromatic aldehyde complex in an amount sufficient to prolong PST blood levels and enhance feed efficiency. The dose is dependent on several factors, for example, the size of the animal and the effect desired. For administration to swine, the complex, preferable, will be in an amount of from 10 mg. to about 500 mg, advantageously from about 30 mg to about 75 mg equal doses will be administered at intervals of about 7 to 42 days.

- 7 -


What is Claimed is:

1. A method for providing a prolonged release of a somatotropin which comprises parenterally administering to an animal organism in an amount sufficient to produce said release a growth promoting agent being a complex of a somatotropin and an aromatic aldehyde having the following formula:



in which X is CHO or CH₂CHO and each of R₁ and R₂ is hydrogen, hydroxy, methoxy, ethoxy, methyl or ethyl.

2. The method of Claim 1 in which X is CHO and each of R₁ and R₂ is hydroxy or methoxy and the somatotropin is selected from the group consisting of porcine, human, bovine, avian, equine and ovine.
3. The method of Claim 2 in which the aldehyde is 2-hydroxy-3-methoxy benzaldehyde and the somatotropin is porcine somatotropin.
4. The method of Claim 1 in which the aromatic aldehyde is present in the complex in an amount of from about 0.5% to about 10% by weight.
5. The method of Claim 1 in which the complex is administered in an amount of from about 10 mg to about 500 mg.
6. The method of Claim 5 in which the administration is done at from about 7 to 42 day intervals.
7. The method of Claim 1 in which the complex is administered subcutaneously as an implant.
8. A growth promoting complex which produces a prolonged release of a somatotropin which comprises a somatotropin and an aromatic aldehyde having the following formula:



in which X is CHO or CH₂CHO and each of R₁ is hydrogen, hydroxy, methoxy, ethoxy, methyl or ethyl.

SUBSTITUTE SHEET

- 8 -

9. The complex of Claim 8 in which X is CHO and each of R₁ and R₂ is hydroxy or methoxy and the somatotropin is selected from the group consisting of porcine, human, bovine, avian, equine and ovine.
10. The complex of Claim 9 in which the aldehyde is 2-hydroxy-3-methoxy benzaldehyde and the somatotropin is porcine somatotropin.
11. A method for improving feed efficiency in animals which comprises administering to an animal organism in an amount sufficient to produce said efficiency the complex of Claim 8.
12. The method of Claim 11 in which the complex is porcine somatotropin and 2-hydroxy-3-methoxy benzaldehyde.
13. The method of Claim 11 in which the complex is administered in an amount of from about 10 mg to about 500 mg.
14. The method of Claim 13 in which the administration is done from about 7 to about 42 day intervals.
15. The method of Claim 11 in which the aromatic aldehyde is present in the complex in an amount of from about 0.5% to about 10% by weight.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/05659

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61K 37/02; C07K 7/10

US CL :514/2, 12, 21; 530/338, 345, 399

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2, 12, 21; 530/338, 345, 399

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

Somatotropin, Aromatic Aldehyde,

Hydroxy(W) Methoxy(W) Benzldehyde

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,015,627 (Linsey et al.) 14 May 1991, See abstract.	1-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 JULY 1993

Date of mailing of the international search report

AUG 18 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

LESTER L. LEE

Telephone No. (703) 308-0196